Susan M. Efler

1.4k total citations
10 papers, 1.2k citations indexed

About

Susan M. Efler is a scholar working on Epidemiology, Immunology and Hepatology. According to data from OpenAlex, Susan M. Efler has authored 10 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 6 papers in Immunology and 3 papers in Hepatology. Recurrent topics in Susan M. Efler's work include Immune Response and Inflammation (6 papers), Immunotherapy and Immune Responses (4 papers) and Hepatitis B Virus Studies (3 papers). Susan M. Efler is often cited by papers focused on Immune Response and Inflammation (6 papers), Immunotherapy and Immune Responses (4 papers) and Hepatitis B Virus Studies (3 papers). Susan M. Efler collaborates with scholars based in United States, Canada and Germany. Susan M. Efler's co-authors include Heather L. Davis, Arthur Μ. Krieg, Curtis Cooper, D. William Cameron, A M Krieg, Mary L. Morris, Lin Yang, Risini D. Weeratna, Tong Wu and Laurie Love-Homan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Hepatology and Journal of Hepatology.

In The Last Decade

Susan M. Efler

10 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan M. Efler United States 9 825 348 328 144 98 10 1.2k
H. L. Davis Canada 11 569 0.7× 329 0.9× 332 1.0× 160 1.1× 61 0.6× 12 968
Minh-Duc Nguyen United States 9 1.3k 1.5× 227 0.7× 390 1.2× 129 0.9× 148 1.5× 9 1.7k
Rose S. Chu United States 7 879 1.1× 248 0.7× 258 0.8× 134 0.9× 145 1.5× 8 1.2k
Cody C. Allison Australia 18 484 0.6× 289 0.8× 316 1.0× 229 1.6× 47 0.5× 34 1.2k
Uma Kavita United States 16 736 0.9× 528 1.5× 375 1.1× 175 1.2× 41 0.4× 19 1.3k
Oleg S. Targoni United States 12 1.1k 1.3× 227 0.7× 324 1.0× 123 0.9× 111 1.1× 18 1.5k
Diego Piccioli Italy 13 985 1.2× 201 0.6× 174 0.5× 98 0.7× 85 0.9× 22 1.3k
Arash Ronaghy United States 10 826 1.0× 178 0.5× 305 0.9× 101 0.7× 97 1.0× 19 1.2k
Chiara Sammicheli Italy 17 543 0.7× 268 0.8× 270 0.8× 177 1.2× 120 1.2× 26 925
Frances Terry United States 22 537 0.7× 322 0.9× 704 2.1× 260 1.8× 67 0.7× 49 1.2k

Countries citing papers authored by Susan M. Efler

Since Specialization
Citations

This map shows the geographic impact of Susan M. Efler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan M. Efler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan M. Efler more than expected).

Fields of papers citing papers by Susan M. Efler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan M. Efler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan M. Efler. The network helps show where Susan M. Efler may publish in the future.

Co-authorship network of co-authors of Susan M. Efler

This figure shows the co-authorship network connecting the top 25 collaborators of Susan M. Efler. A scholar is included among the top collaborators of Susan M. Efler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan M. Efler. Susan M. Efler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Cooper, Curtis, N Ahluwalia, Susan M. Efler, et al.. (2008). Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers. PubMed. 6(1). 3–3. 16 indexed citations
2.
McHutchison, John G., Bruce R. Bacon, Stuart C. Gordon, et al.. (2007). Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology. 46(5). 1341–1349. 94 indexed citations
3.
Vicari, Alain, Tess Schmalbach, Julie Lekstrom-Himes, et al.. (2007). Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.. PubMed. 12(5). 741–51. 33 indexed citations
4.
Vicari, Alain, Tess Schmalbach, Julie Lekstrom-Himes, et al.. (2007). Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON™), an Investigational Synthetic Toll-like Receptor 9 Agonist. Antiviral Therapy. 12(5). 741–751. 33 indexed citations
5.
McHutchison, John G., Bruce R. Bacon, Stuart C. Gordon, et al.. (2006). 111 Final results of a multi-center phase 1b, randomized, placebo-controlled, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus. Journal of Hepatology. 44. S49–S49. 7 indexed citations
6.
7.
8.
Cooper, Curtis, Heather L. Davis, Mary L. Morris, et al.. (2004). CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B� HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study. Journal of Clinical Immunology. 24(6). 693–701. 270 indexed citations
9.
Cooper, Curtis, Heather L. Davis, Mary L. Morris, et al.. (2004). Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 22(23-24). 3136–3143. 209 indexed citations
10.
Krieg, Arthur Μ., Tong Wu, Risini D. Weeratna, et al.. (1998). Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proceedings of the National Academy of Sciences. 95(21). 12631–12636. 328 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. L. Davis Breakdown of academic impact, for papers by Minh-Duc Nguyen Breakdown of academic impact, for papers by Rose S. Chu Breakdown of academic impact, for papers by Cody C. Allison Breakdown of academic impact, for papers by Uma Kavita Breakdown of academic impact, for papers by Oleg S. Targoni Breakdown of academic impact, for papers by Diego Piccioli Breakdown of academic impact, for papers by Arash Ronaghy Breakdown of academic impact, for papers by Chiara Sammicheli Breakdown of academic impact, for papers by Frances Terry
Rankless by CCL
2026